Cryptosporidium in humans and animals-a one health approach to prophylaxis

U Ryan1, A Zahedi2, A Paparini2

  • 1School of Veterinary and Life Sciences, Murdoch University, Perth, WA, Australia. Una.Ryan@murdoch.edu.au.

Parasite Immunology
|July 26, 2016
PubMed

Insights

Cryptosporidium causes severe diarrhea globally, with zoonotic potential. A One Health approach integrating veterinary, medical, and environmental efforts is crucial for controlling this parasitic infection due to a lack of vaccines and treatments.

Area of Science:

  • Parasitology
  • Public Health
  • Immunology
  • One Health

Background:

  • Cryptosporidium is a leading cause of human diarrhea worldwide, second to rotavirus.
  • Zoonotic transmission and environmental persistence contribute to foodborne and waterborne outbreaks.
  • Cryptosporidium hominis and Cryptosporidium parvum are the primary species causing human infections.

Purpose of the Study:

  • To review the One Health approach for cryptosporidiosis prophylaxis.
  • To highlight the importance of understanding zoonotic transmission routes.
  • To discuss improvements in sanitation, risk management, diagnosis, treatment, and vaccine development.

Main Methods:

  • This is a review article, synthesizing existing knowledge on Cryptosporidium.
  • Focuses on a One Health framework for disease control.
  • Examines aspects of transmission, host immunity, and therapeutic/prophylactic strategies.

Main Results:

  • Host immune status significantly impacts cryptosporidiosis severity, from self-limiting in immunocompetent individuals to fatal in immunocompromised ones.
  • Effective drugs and vaccines are currently unavailable.
  • Cross-disciplinary collaboration is essential for effective disease control.

Conclusions:

  • A comprehensive One Health strategy is vital for controlling zoonotic Cryptosporidium.
  • Key elements include understanding transmission, enhancing sanitation and risk management, and improving diagnostics and treatments.
  • The development of an effective anticryptosporidial vaccine remains a critical future goal.